Clinical Trials
123
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (94 trials with phase data)• Click on a phase to view related trials
The Impact of Time Restricted Eating on Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 10
- Registration Number
- NCT06887543
- Locations
- 🇺🇸
The Rockefeller University Hospital, New York, New York, United States
Thermogenic Silencer Regulatory Factors in Humans
- Conditions
- Metabolic DiseaseObesityCold Exposure
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 120
- Registration Number
- NCT06424132
- Locations
- 🇺🇸
Rockefeller University, New York, New York, United States
Myokine Identification Following Acute Exercise
- Conditions
- Adiposity
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 12
- Registration Number
- NCT06223035
- Locations
- 🇺🇸
Rockefeller University, New York, New York, United States
Compassion-Based Resiliency Training (CBRT) Intervention on Racism-based Stress
- Conditions
- Stress, PsychologicalRacism
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 22
- Registration Number
- NCT06146218
- Locations
- 🇺🇸
Recrutment Office, New York, New York, United States
HepB MAb19 in Individuals with Chronic Hepatitis B Infection
- Conditions
- Hepatitis B VirusHepatitis B
- Interventions
- Other: Sterile Saline
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 37
- Registration Number
- NCT05856890
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸The Rockefeller University, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 25
- Next
News
Insights into Fibrolamellar Carcinoma Lead to New Clinical Trial
• Researchers have identified a unique transcriptomic signature for fibrolamellar hepatocellular carcinoma (FLC), distinguishing it from other liver cancers. • A clinical trial has been initiated, combining DT2216 and irinotecan, showing promise in preliminary results against FLC. • The study highlights the importance of examining tumor margins for hidden FLC cells to prevent potential recurrence. • The research suggests defining cancer by its impact on protein activity balance rather than solely by DNA changes.
Novel Enzyme Shows Promise in Treating IgG-Mediated Autoimmune Diseases
Researchers at Emory University have identified a novel enzyme, CU43, that effectively reduces IgG-mediated pathologies in mouse models of autoimmune diseases.